Financial Management Company Douglas Lane Raised Its Thermo Fisher Stake. Is the Stock a Buy?

Douglas Lane & Associates increased its position in Thermo Fisher Scientific (TMO) by 16,745 shares, a $7.79 million purchase, bringing its total holding to 1.5% of its assets under management as of Q3 2025. This move suggests the wealth manager views TMO as attractively valued following a 12% stock decline over the past year and a lower P/E ratio. The investment is supported by Thermo Fisher's strong Q2 fiscal performance, which included 3% revenue growth to $10.9 billion and a 6% increase in diluted EPS to $4.28, alongside raised 2025 fiscal guidance to $44 billion in sales.

Analysis

Douglas Lane & Associates significantly increased its position in Thermo Fisher Scientific (TMO) by 16,745 shares, a transaction valued at approximately $7.79 million, bringing TMO to 1.5% of the fund's reportable assets. This move signals a strong conviction in TMO's value proposition, particularly after the stock experienced a 12% decline over the trailing 12 months, suggesting an attractive entry point for the wealth manager.

Thermo Fisher Scientific's recent financial performance supports this bullish stance, with Q2 fiscal revenue growing 3% to $10.9 billion and diluted EPS increasing 6% year-over-year to $4.28. The company further reinforced its positive outlook by raising its 2025 fiscal guidance to approximately $44 billion in sales, up from $42.9 billion in the prior year.

The company's robust fundamentals, including its diversified revenue streams across life sciences, diagnostics, and biopharma services, combined with a lower price-to-earnings (P/E) ratio compared to a year ago, present a compelling investment case. Douglas Lane's increased stake underscores a belief that TMO's current valuation does not fully reflect its consistent earnings growth and market leadership.

Key Decisions for Investors

• Investors should evaluate Thermo Fisher Scientific's (TMO) current valuation, considering its recent 12% stock decline and lower P/E ratio, against its strong Q2 earnings and raised 2025 guidance.
• Monitor TMO's continued execution on its raised fiscal guidance and its ability to maintain diversified revenue growth in the life sciences and biopharma sectors.
• Consider the implications of a sophisticated wealth management firm like Douglas Lane & Associates increasing its stake, which suggests a perceived undervaluation and strong long-term prospects.